… Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their …

… with VKA reduces venous thromboembolic events but not mortality. The decision for a patient
with cancer and VTE to start long‐term LMWH versus oral anticoagulation should balance …

… with 5 years of extended anticoagulation vs no anticoagulation in patients with different …
deaths with 5 years of extended anticoagulation vs no anticoagulation in patients with different …

… using the terms venous thromboembolism or pulmonary … or anticoagulant(s) or anticoagulant
treatment or anticoagulant therapy or duration of anticoagulant therapy or anticoagulation. …

… The duration of oral anticoagulant therapy after a second episode of venous … control VTE
population (risk ratio, 2.1; 95% CI, 1.3-3.3) within 4 years following cessation of anticoagulation; …

… Patients with cancer have a substantially increased risk of venous thromboembolism (VTE) …
Furthermore, intriguing in vitro and animal findings suggest that anticoagulants, in particular …

… D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism:
… unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. …

… Venous thromboembolism (VTE) carries a considerable risk of recurrence and anticoagulants
should be administered for a minimum of three months. Since little is known about real life …

… of anticoagulation in prevention of venous thromboembolism in patients with ICH because
the use of anticoagulants … To further clarify the role of anticoagulants (unfractionated heparin […

… The decision for a person with cancer and venous thromboembolism (VTE) to start long‐term
low molecular weight heparin (LMWHs) treatment or oral anticoagulation treatment should …